world cancer report - iarc

Fig. 5.134 Ten-year relative survival for melanoma,
according to stage.
nique enables mapping of the lymphatics
in the skin by lymphoscintigraphy:
radioactive tracer is injected at the site of
the primary and its flow through the skin
to the first lymph node that takes up the
REFERENCES
1. Ferlay J, Bray F, Parkin DM, Pisani P (2001) Globocan
2000: Cancer Incidence and Mortality Worldwide (IARC
Cancer Bases No. 5), Lyon, IARCPress.
2. IARC (1992) Solar and Ultraviolet Radiation (IARC
Monographs on the Evaluation of Carcinogenic Risks to
Humans, Vol. 55), Lyon, IARCPress.
3. Aitken JF, Duffy DL, Green A, Youl P, MacLennan R,
Martin NG (1994) Heterogeneity of melanoma risk in families
of melanoma patients. Am J Epidemiol, 140: 961-973.
4. Steiner A, Pehamberger H, Wolff K (1987) In vivo epiluminescence
microscopy of pigmented skin lesions. II.
Diagnosis of small pigmented skin lesions and early detection
of malignant melanoma. J Am Acad Dermatol, 17: 584-
591.
5. Schaffer JV, Bolognia JL (2001) The melanocortin-1
receptor: red hair and beyond. Arch Dermatol, 137: 1477-
1485.
6. Pollock PM, Trent JM (2000) The genetics of cutaneous
melanoma. Clin Lab Med, 20: 667-690.
7. Goldstein AM, Chidambaram A, Halpern A, Holly EA,
Guerry ID, Sagebiel R, Elder DE, Tucker MA (2002) Rarity of
CDK4 germline mutations in familial melanoma. Melanoma
Res, 12: 51-55.
256 Human cancers by organ site
tracer (the sentinel node) is identified.
This lymph node is then removed for
histopathological examination; only patients
with positive lymph nodes are subjected
to full lymph node dissection.
However, pending completion of an international
trial, the survival benefit of this
technique is unknown.
Metastatic melanoma
The greater the number of nodes involved,
the higher the risk of systemic metastases
and poor prognosis. As the thickness of the
melanoma increases and as the number of
lymph nodes involved rises, the risk of systemic
metastases becomes greater.
Melanoma metastasizes widely, with the
lungs, liver and brain being the most common
sites. Vitiligo (a skin condition characterized
by failure to form melanin) is a
favourable prognostic sign in metastatic
melanoma. At the present time, only a small
8. Halachmi S, Gilchrest BA (2001) Update on genetic
events in the pathogenesis of melanoma. Curr Opin Oncol,
13: 129-136.
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S et
al. (2002) Mutations of the BRAF gene in human cancer.
Nature, 417: 949-954.
10. National Health and Medical Research Council, ed.
(1999) Clinical Practice Guidelines. The Management of
Cutaneous Melanoma.
11. Morton DL (2001) Lymphatic mapping and sentinel
lymphadenectomy for melanoma: past, present and future.
Ann Surg Oncol, 8: 22S-28S.
12. Coates AS (1992) Systemic chemotherapy for malignant
melanoma. World J Surg, 16: 277-281.
13. Helmbach H, Rossmann E, Kern MA, Schadendorf D
(2001) Drug-resistance in human melanoma. Int J Cancer,
93: 617-622.
14. Weber JS, Aparicio A (2001) Novel immunologic
approaches to the management of malignant melanoma.
Curr Opin Oncol, 13: 124-128.
15. Hersey P (2002) Advances in the non-surgical treatment
of melanoma. Expert Opin Investig Drugs, 11: 75-85.
proportion of people (